San Diego-based Viking Therapeutics marked alone as a serious competitor during the weight loss drug market in February soon after revealing promising info from the mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered being a weekly injection and in March the company unveiled